Ethnicity and adverse drug reactions

British Medical Journal

Volumn 332, Issue 7551, 2006, Pages 1163-1164

  Eliasson, Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HLA B ANTIGEN;

ANGIONEUROTIC EDEMA; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; ETHNOLOGY; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; META ANALYSIS; OPTIMAL DRUG DOSE; PHARMACOGENETICS; PRIORITY JOURNAL; RELAPSE; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; DRUG TOXICITY; ETHNIC GROUP; GENETICS; NOTE;

DRUG TOXICITY; ETHNIC GROUPS; GENETIC MARKERS; HUMANS;

EID: 33646909147     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.332.7551.1163     Document Type: Editorial

References (12)

1. Foster MW, Sharp RR. Beyond race: towards a whole genome perspective on human populations and genetic variation. Nature Rev Genet 2004;5:790-5.
2. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med 2003;348:1166-70.
3. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332:1177-80.
4. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nature Genetics 2005;37:671-81.
5. Yue Q-Y, Svensson J-O, Sjöqvist F, Säwe J. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinsese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:643-7.
6. Johansson I, Oscarsson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450 2D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
7. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001;22:298-305.
8. Xie H-G, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001;41:815-50.
9. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
10. Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-Q Ho H-C, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428:486.
11. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, Lelouet H, et al. A marker for Stevens-Johnson syndrome; ethnicity matters. Pharmacogenomics J 2006 Jan 17; doi:10.1038/sj.tpj.6500356.
12. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity to abacavir. Lancet 2002;359:1121-2.